COLUMBUS, Ohio and FAYETTEVILLE, Ark. , July 25, 2024 /PRNewswire/ -- Paradigm and Highlands Oncology announce promising results from their ongoing collaboration, demonstrating a 45% increase in the number of patients enrolled in clinical trials. The achievement aligns with the objectives to maximize the availability of clinical trials for all patients in the region.
Highlands is a large, community oncology cancer center located in the northwest Arkansas corridor, which provides care not only to Arkansas , but to surrounding Oklahoma and Missouri . " Northwest Arkansas is a wonderful place to live, work and raise a family, however, there are tremendous geographical barriers to participation in university-based clinical research programs in the region," said J. Thaddeus Beck , MD, FACP, Co-Founder and Medical Director of Research at Highlands Oncology.
"Highlands is dedicated to providing the highest quality of cancer care as well as fulfilling the need for patient access to clinical trials in our community." "Access to cancer care varies dramatically depending on where you live," said Kent Thoelke , CEO, Paradigm. "We're proud to help create more equitable access to clinical trials for patients in Arkansas through our work with Highlands, as well as in similar communities across the US.
We imagine a world where everyone can get the most advanced care possible, no matter their geography." Highlands works with Paradigm to evaluate the feasibility of new clinical trials and scre.